Reimbursed Care Access in Latvia

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Evidence of prohibition and penal sanctions is reflected in Latvia’s controlled‑substances framework and national summaries of illegal status for ‘magic mushrooms’. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is listed under international/Latvian controlled substance obligations and carries criminal penalties for possession and trafficking under Latvian law. # #.

Esketamine (Spravato) is authorised for medical use in the European Union and therefore may be legally supplied in Latvia under prescription and supervised administration requirements; the EMA authorisation describes restrictions (special prescription and direct supervision) tied to its safety profile. #.

At the national/regulatory level, changes and notifications to Latvia’s controlled substance regulations explicitly reference esketamine in the context of the national controlled‑substances lists and regulatory updates, which is consistent with enabling authorised medical use under supervision domestically. This inclusion means esketamine is handled as a controlled medicinal product in Latvia and may be supplied through authorised medical channels; local distributor/marketing authorisation records indicate commercial presence through Latvian pharmaceutical companies. # #.

Reimbursement and access nuance: while esketamine is authorised, routine public reimbursement (full coverage through national health insurance) is not uniformly automatic across EU member states and depends on national HTA/pricing and reimbursement decisions. Latvia’s pharmaceutical reimbursement framework uses national lists and co‑payment regimes; available public information on Latvian medicines pricing and reimbursement administration indicates that high‑cost, specialist medicines may require separate reimbursement decisions and frequently involve partial patient co‑payments or private payment pathways in practice. Therefore, in Latvia esketamine is available as a prescription, supervised medicine, but patients should expect that access for depression will typically be via specialised psychiatric services and may be private or subject to separate reimbursement review. #.

Ketamine is a controlled medicine used routinely in Latvia for anaesthesia and emergency medicine, and it is legally available in clinical settings under prescription for licensed indications. Off‑label use of ketamine (eg, intravenous infusions for treatment‑resistant depression) is practised internationally and is used in some private/clinical settings in Europe, and the same off‑label framework applies in Latvia: prescribing a licensed medicine for an unlicensed indication is a medical decision made by treating clinicians within national professional and legal norms. Latvia’s regulatory framework requires certification/permits for carrying certain narcotic/psychotropic medicines for medical use, and patients transporting controlled medicines for medical needs must have appropriate documentation issued/confirmed by health inspection authorities. # #.

Reimbursement and delivery: off‑label psychiatric use of ketamine (intravenous or intranasal generic ketamine) is typically delivered in specialised hospital or private clinic settings. Across many countries (and in Latvia by extension) such off‑label ketamine treatments are normally not part of routine publicly reimbursed packages unless a formal national reimbursement/HTA decision is taken; they are commonly self‑pay or provided through private arrangements. Clinicians must follow national standards of care and controlled‑substances handling rules when administering ketamine. (No public evidence was found that Latvia has a national programme providing routine public reimbursement specifically for ketamine in psychiatric indications as of the latest regulatory notices.) # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (and DMT‑containing preparations such as ayahuasca) are treated as controlled substances in Latvia; possession, production and trafficking carry criminal penalties. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Latvian controlled‑substance regulation and recent updates to the national lists treat novel and classical hallucinogens as prohibited outside approved research contexts. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of legal access or reimbursement pathways for ibogaine in Latvia; international summaries list ibogaine as illegal or unregulated in many jurisdictions and as not authorised for medical use in Latvia outside research. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws when containing internationally controlled components (notably DMT), with no authorized medical use outside of approved clinical research. While the law may not always name plant preparations explicitly, DMT content makes ayahuasca subject to the same controls and criminal penalties in Latvia. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and peyote preparations where relevant) is controlled under international conventions and Latvian scheduling, and there is no routine medical access or reimbursement in Latvia. # #.

Currently classified as a strictly controlled substance or analogue covered by Latvia’s controlled‑substances legislation and analogue provisions, with no authorized medical use outside of approved clinical research. Latvia has used analogue/structural descriptions and periodic amendments to include new synthetic psychoactive compounds (including 2C family derivatives) under control. # #.